Paste a nucleotide (DNA) or amino acid sequence of an alpaca, llama, or camel antibody domain:
Screen candidate alpaca or camel nanobodies from phage display, yeast display, or single B-cell sequencing. Classifies each clone into Autonomous VHH vs Conventional VH and evaluates the FR2 tetrad, solubility score, and synthesis boundaries.
High-throughput profiling for Camelid NGS libraries (Illumina / PacBio / Oxford Nanopore). Calculates the **VHH vs Conventional VH ratio**, **CDR3 length distribution spectrum**, and **non-canonical Cys-Cys interloop frequency**.
The foundational clinical nanobodies and experimental landmarks that defined single-domain antibody therapeutics:
| Nanobody / Clone | Target Antigen | Therapeutic / Status | Hallmark Tetrad | Boundary | Length | Action |
|---|
In their groundbreaking 1993 Nature discovery ("Naturally occurring antibodies devoid of light chains", Nature 363, 446–448), the Hamers laboratory demonstrated that sera from dromedary camels (*Camelus dromedarius*) and later alpacas and llamas contain functional homodimeric IgG antibodies lacking both light chains and constant CH1 domains. This revolutionized antibody biochemistry.
Serge Muyldermans pioneered the structural biophysics, crystallization, and immunogenetic classification of single-domain nanobodies. He uncovered the canonical Framework 2 hallmark tetrad substitutions that remodel the hydrophobic VL-interface into a hydrophilic convex surface, preventing aggregation without requiring a light chain partner.
Pioneered the application of nanobodies as crystallization chaperones and conformational biosensors. Steyaert's work enabled atomic-resolution cryo-EM and X-ray crystal structures of elusive GPCRs, ion channels, and dynamic protein complexes that were previously unresolvable using conventional antibodies.